© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Washington, D.C. - Responding to concerns over increased malignancies seen in animal studies, a pediatric subcommittee of the FDA's Anti-Infective Drugs Advisory Committee said topical immunosuppressant labeling should include a warning against use in children under the age of two.